Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is...
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
...
UC San Diego Moores Cancer Center, La Jolla, California, United States
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Samsung Medical Center, Seoul, Korea, Republic of
Samsung Medical Center, Seoul, Korea, Republic of
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Araba of University Hospital, Vitoria-Gasteiz, Araba, Spain
Northside Hospital, Atlanta, Georgia, United States
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
Dana Farber Cancer Institute/Brigham & Women's Hospital, Boston, Massachusetts, United States
Boston University, Boston, Massachusetts, United States
Dana Farber Cancer Institute/Massachusetts General Hospital, Boston, Massachusetts, United States
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.